Header Logo

Connection

Mark Pollack to Anxiety Disorders

Back to Details
This is a "connection" page, showing publications Mark Pollack has written about Anxiety Disorders.
Mark Pollack
Connection Strength
13.135
Anxiety Disorders
  1. Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions. Biol Psychiatry. 2016 08 15; 80(4):274-283.
    View in: PubMed
    Score: 0.473
  2. Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp Clin Trials. 2015 Jul; 43:223-30.
    View in: PubMed
    Score: 0.465
  3. Refractory generalized anxiety disorder. J Clin Psychiatry. 2009; 70 Suppl 2:32-8.
    View in: PubMed
    Score: 0.297
  4. Introduction to the special issue: anxiety disorders in cross-cultural perspective. CNS Neurosci Ther. 2009; 15(3):207-9.
    View in: PubMed
    Score: 0.297
  5. Anxiety disorder presentations in Asian populations: a review. CNS Neurosci Ther. 2009; 15(3):295-303.
    View in: PubMed
    Score: 0.297
  6. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008 Jun; 28(3):308-16.
    View in: PubMed
    Score: 0.285
  7. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008 May; 65(5):551-62.
    View in: PubMed
    Score: 0.283
  8. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008 Oct; 42(14):1176-84.
    View in: PubMed
    Score: 0.281
  9. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008 May; 197(4):675-81.
    View in: PubMed
    Score: 0.279
  10. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
    View in: PubMed
    Score: 0.278
  11. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety. 2008; 25(6):467-76.
    View in: PubMed
    Score: 0.277
  12. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 01; 32(3):739-43.
    View in: PubMed
    Score: 0.275
  13. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry. 2007 Jul; 68(7):1010-3.
    View in: PubMed
    Score: 0.267
  14. The relationship of anxiety disorders, anxiety sensitivity and pulmonary dysfunction with dyspnea-related distress and avoidance. J Nerv Ment Dis. 2006 Dec; 194(12):951-7.
    View in: PubMed
    Score: 0.257
  15. The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. J Psychiatr Res. 2007 Apr-Jun; 41(3-4):255-64.
    View in: PubMed
    Score: 0.255
  16. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006 Mar; 67(3):381-5.
    View in: PubMed
    Score: 0.244
  17. Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anxiety. 2006; 23(6):373-6.
    View in: PubMed
    Score: 0.241
  18. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov; 66(11):1401-8.
    View in: PubMed
    Score: 0.238
  19. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 01; 59(3):211-5.
    View in: PubMed
    Score: 0.236
  20. Rates of isolated sleep paralysis in outpatients with anxiety disorders. J Anxiety Disord. 2006; 20(5):687-93.
    View in: PubMed
    Score: 0.235
  21. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005 Jan; 20(1):9-11.
    View in: PubMed
    Score: 0.225
  22. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. J Clin Psychiatry. 2005; 66 Suppl 2:21-7.
    View in: PubMed
    Score: 0.225
  23. Comorbid anxiety and depression. J Clin Psychiatry. 2005; 66 Suppl 8:22-9.
    View in: PubMed
    Score: 0.225
  24. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004 Dec; 161(12):2222-9.
    View in: PubMed
    Score: 0.224
  25. Unmet needs in the treatment of anxiety disorders. Psychopharmacol Bull. 2004; 38(1):31-7.
    View in: PubMed
    Score: 0.210
  26. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003 Jun; 23(3):250-9.
    View in: PubMed
    Score: 0.201
  27. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003; 64 Suppl 15:40-5.
    View in: PubMed
    Score: 0.196
  28. History of childhood abuse in panic disorder, social phobia, and generalized anxiety disorder. J Nerv Ment Dis. 2002 Jul; 190(7):453-6.
    View in: PubMed
    Score: 0.189
  29. Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. J Affect Disord. 2002 May; 69(1-3):209-17.
    View in: PubMed
    Score: 0.187
  30. New advances in the management of anxiety disorders. Psychopharmacol Bull. 2002; 36(4):79-94.
    View in: PubMed
    Score: 0.183
  31. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001 May; 62(5):350-7.
    View in: PubMed
    Score: 0.174
  32. Prevalence of childhood ADHD among patients with Generalized Anxiety Disorder and a comparison condition, Social Phobia. Depress Anxiety. 2001; 13(4):190-1.
    View in: PubMed
    Score: 0.170
  33. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry. 2001; 62 Suppl 19:20-5.
    View in: PubMed
    Score: 0.170
  34. Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. J Anxiety Disord. 2019 12; 68:102149.
    View in: PubMed
    Score: 0.156
  35. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998 Jul; 155(7):992-3.
    View in: PubMed
    Score: 0.143
  36. Examining the Relationship Between Parent and Child Psychopathology in Treatment-Seeking Veterans. Child Psychiatry Hum Dev. 2018 04; 49(2):209-216.
    View in: PubMed
    Score: 0.141
  37. Anxiety sensitivity moderates drug cravings in response to induced negative affect in opioid dependent outpatients. Addict Behav. 2018 09; 84:75-78.
    View in: PubMed
    Score: 0.140
  38. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry. 1997 Dec; 9(4):241-5.
    View in: PubMed
    Score: 0.138
  39. Prevalence of body dysmorphic disorder in patients with anxiety disorders. J Anxiety Disord. 1997 Sep-Oct; 11(5):499-502.
    View in: PubMed
    Score: 0.135
  40. The hidden costs of untreated anxiety disorders. Harv Rev Psychiatry. 1997 May-Jun; 5(1):40-2.
    View in: PubMed
    Score: 0.132
  41. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry. 2017 05 01; 74(5):501-510.
    View in: PubMed
    Score: 0.132
  42. The effect of mindfulness meditation training on biological acute stress responses in generalized anxiety disorder. Psychiatry Res. 2018 04; 262:328-332.
    View in: PubMed
    Score: 0.130
  43. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997; 58 Suppl 11:19-23.
    View in: PubMed
    Score: 0.129
  44. Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord. 1996 Nov 25; 41(2):135-9.
    View in: PubMed
    Score: 0.128
  45. Relationship of childhood anxiety to adult panic disorder: correlates and influence on course. Am J Psychiatry. 1996 Mar; 153(3):376-81.
    View in: PubMed
    Score: 0.122
  46. ADULT ANXIETY DISORDERS IN RELATION TO TRAIT ANXIETY AND PERCEIVED STRESS IN CHILDHOOD. Psychol Rep. 2015 Oct; 117(2):473-89.
    View in: PubMed
    Score: 0.118
  47. Altered resting-state functional connectivity of the frontal-striatal reward system in social anxiety disorder. PLoS One. 2015; 10(4):e0125286.
    View in: PubMed
    Score: 0.115
  48. D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update. Curr Psychiatry Rep. 2015 Jan; 17(1):532.
    View in: PubMed
    Score: 0.112
  49. Influence of RGS2 on sertraline treatment for social anxiety disorder. Neuropsychopharmacology. 2014 May; 39(6):1340-6.
    View in: PubMed
    Score: 0.104
  50. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry. 2013 Aug; 74(8):786-92.
    View in: PubMed
    Score: 0.102
  51. Cortico-limbic responses to masked affective faces across ptsd, panic disorder, and specific phobia. Depress Anxiety. 2014 Feb; 31(2):150-9.
    View in: PubMed
    Score: 0.102
  52. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res. 2013 Oct; 47(10):1455-61.
    View in: PubMed
    Score: 0.102
  53. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry. 2013 Jan; 70(1):87-97.
    View in: PubMed
    Score: 0.098
  54. Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry. 1990 Dec; 51 Suppl A:12-6.
    View in: PubMed
    Score: 0.085
  55. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr. 2010 Jul; 15(7):367-73.
    View in: PubMed
    Score: 0.082
  56. Long-term management of panic disorder. J Clin Psychiatry. 1990 May; 51 Suppl:11-3; discussion 50-3.
    View in: PubMed
    Score: 0.081
  57. A comparison of emotional approach coping (EAC) between individuals with anxiety disorders and nonanxious controls. CNS Neurosci Ther. 2009; 15(2):100-6.
    View in: PubMed
    Score: 0.074
  58. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008 Aug; 23(6):519-26.
    View in: PubMed
    Score: 0.072
  59. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Neuropsychopharmacology. 2009 Jan; 34(2):390-8.
    View in: PubMed
    Score: 0.071
  60. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008 Jun; 13(6):522-7.
    View in: PubMed
    Score: 0.071
  61. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
    View in: PubMed
    Score: 0.070
  62. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depress Anxiety. 2008; 25(2):167-71.
    View in: PubMed
    Score: 0.069
  63. Ataque de nervios: relationship to anxiety sensitivity and dissociation predisposition. Depress Anxiety. 2008; 25(6):489-95.
    View in: PubMed
    Score: 0.069
  64. Anxiety is associated with impulsivity in bipolar disorder. J Anxiety Disord. 2008 Jun; 22(5):868-76.
    View in: PubMed
    Score: 0.068
  65. Posttraumatic stress disorder symptoms following media exposure to tragic events: impact of 9/11 on children at risk for anxiety disorders. J Anxiety Disord. 2007; 21(7):888-902.
    View in: PubMed
    Score: 0.065
  66. Prediction of "fear" acquisition in healthy control participants in a de novo fear-conditioning paradigm. Behav Modif. 2007 Jan; 31(1):32-51.
    View in: PubMed
    Score: 0.065
  67. Cross-cultural differences in somatic presentation in patients with generalized anxiety disorder. J Nerv Ment Dis. 2006 Dec; 194(12):962-6.
    View in: PubMed
    Score: 0.064
  68. Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol. 1986 Oct; 6(5):302-4.
    View in: PubMed
    Score: 0.063
  69. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev. 2006 Fall-Winter; 12(3-4):208-17.
    View in: PubMed
    Score: 0.063
  70. Understanding the link between anxiety symptoms and suicidal ideation and behaviors in outpatients with bipolar disorder. J Affect Disord. 2007 Jan; 97(1-3):91-9.
    View in: PubMed
    Score: 0.062
  71. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006 Jul; 189:20-5.
    View in: PubMed
    Score: 0.062
  72. Effects of parental anxiety disorders in children at high risk for panic disorder: a controlled study. J Affect Disord. 2006 Aug; 94(1-3):191-7.
    View in: PubMed
    Score: 0.062
  73. Anxiety sensitivity in traumatized Cambodian refugees: a discriminant function and factor analytic investigation. Behav Res Ther. 2005 Dec; 43(12):1631-43.
    View in: PubMed
    Score: 0.060
  74. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 Sep; 62(9):1022-30.
    View in: PubMed
    Score: 0.059
  75. Discussion: using benzodiazepines in clinical practice. J Clin Psychiatry. 2005; 66 Suppl 2:39-43; quiz 44-5.
    View in: PubMed
    Score: 0.056
  76. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
    View in: PubMed
    Score: 0.054
  77. Exploring the psychometric properties and construct validity of the MCMI-III anxiety and avoidant personality scales. J Pers Assess. 2003 Dec; 81(3):237-41.
    View in: PubMed
    Score: 0.052
  78. What good are positive emotions for treatment? A replication test of whether trait positive emotionality predicts response to exposure therapy for social anxiety disorder. Behav Res Ther. 2023 12; 171:104436.
    View in: PubMed
    Score: 0.052
  79. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):53-61.
    View in: PubMed
    Score: 0.051
  80. Using pre-treatment de novo threat conditioning outcomes to predict treatment response to DCS augmentation of exposure-based CBT. J Psychiatr Res. 2023 08; 164:357-363.
    View in: PubMed
    Score: 0.051
  81. Targeted genome screen of panic disorder and anxiety disorder proneness using homology to murine QTL regions. Am J Med Genet. 2001 Mar 08; 105(2):195-206.
    View in: PubMed
    Score: 0.043
  82. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety. 2001; 13(4):166-78.
    View in: PubMed
    Score: 0.043
  83. Childhood history of anxiety disorders among adults with social phobia: rates, correlates, and comparisons with patients with panic disorder. Depress Anxiety. 2001; 14(4):209-13.
    View in: PubMed
    Score: 0.043
  84. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000 Jun; 157(6):968-74.
    View in: PubMed
    Score: 0.041
  85. Quality of life in patients with panic disorder. J Nerv Ment Dis. 1999 Jul; 187(7):429-34.
    View in: PubMed
    Score: 0.038
  86. Anxiety in patients with pulmonary disease: comorbidity and treatment. Semin Clin Neuropsychiatry. 1999 Apr; 4(2):84-97.
    View in: PubMed
    Score: 0.038
  87. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics. 1998 Jan-Feb; 39(1):24-9.
    View in: PubMed
    Score: 0.035
  88. Prevalence and correlates of anger attacks: a two site study. J Affect Disord. 1996 Jun 20; 39(1):31-8.
    View in: PubMed
    Score: 0.031
  89. Hemispheric laterality and memory bias for threat in anxiety disorders. J Abnorm Psychol. 1994 Nov; 103(4):828-831.
    View in: PubMed
    Score: 0.028
  90. Sleep panic attacks: an association with childhood anxiety and adult psychopathology. Biol Psychiatry. 1994 Jul 01; 36(1):57-60.
    View in: PubMed
    Score: 0.027
  91. Childhood history of anxiety in adults with panic disorder: association with anxiety sensitivity and comorbidity. Harv Rev Psychiatry. 1994 Jan-Feb; 1(5):288-93.
    View in: PubMed
    Score: 0.026
  92. Personality disorders in patients with panic disorder: association with childhood anxiety disorders, early trauma, comorbidity, and chronicity. Compr Psychiatry. 1992 Mar-Apr; 33(2):78-83.
    View in: PubMed
    Score: 0.023
  93. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991 Feb; 52(2):69-76.
    View in: PubMed
    Score: 0.021
  94. Clonazepam: a review of open clinical trials. J Clin Psychiatry. 1987 Oct; 48 Suppl:12-5.
    View in: PubMed
    Score: 0.017
  95. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry. 1987 Oct; 48 Suppl:16-21.
    View in: PubMed
    Score: 0.017
  96. On panic attacks and neurologic problems. Am J Psychiatry. 1986 Dec; 143(12):1626-7.
    View in: PubMed
    Score: 0.016
  97. Complicated grief and its correlates in patients with bipolar disorder. J Clin Psychiatry. 2005 Sep; 66(9):1105-10.
    View in: PubMed
    Score: 0.015
  98. Childhood antecedents to panic disorder in referred and nonreferred adults. J Child Adolesc Psychopharmacol. 2005 Aug; 15(4):549-61.
    View in: PubMed
    Score: 0.015
  99. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004 Oct; 24(5):512-20.
    View in: PubMed
    Score: 0.014
  100. History of childhood attention deficit hyperactivity disorder (ADHD) features among adults with panic disorder. J Affect Disord. 2000 May; 58(2):99-106.
    View in: PubMed
    Score: 0.010
  101. Predicting prospective episodes of depression in patients with panic disorder: a longitudinal study. J Consult Clin Psychol. 1994 Apr; 62(2):359-65.
    View in: PubMed
    Score: 0.007
  102. Alcohol dependence in panic disorder patients. J Psychiatr Res. 1992 Jan; 26(1):29-38.
    View in: PubMed
    Score: 0.006
  103. Clonazepam for the treatment of social phobia. J Clin Psychiatry. 1990 Nov; 51(11):470-2.
    View in: PubMed
    Score: 0.005
  104. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry. 1990 Jan; 51(1):25-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.